Maria Karvouni

Huddinge, AB, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Oncolytic HSV1716 attenuates tumor-killing activity of infected primary NK cells.

Oncolytic HSV1716 attenuates tumor-killing activity of infected primary NK cells.

Journal: Frontiers in immunology
Published: May 30, 2026

Cellular Immune Response in Horses After West Nile Neuroinvasive Disease.

Cellular Immune Response in Horses After West Nile Neuroinvasive Disease.

Journal: Animals : an open access journal from MDPI
Published: June 30, 2025

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.

Journal: Cytotherapy
Published: September 13, 2022

Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells.

Assessment of T Cell Receptor Complex Expression Kinetics in Natural Killer Cells.

Journal: Current issues in molecular biology
Published: June 16, 2022

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.

Journal: Cancer immunology, immunotherapy : CII
Published: April 11, 2022

Engineered NK Cells Against Cancer and Their Potential Applications Beyond.

Engineered NK Cells Against Cancer and Their Potential Applications Beyond.

Journal: Frontiers in immunology
Published: November 30, 2021

Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).

Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).

Journal: American journal of hematology
Published: March 02, 2021

The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.

The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.

Journal: Frontiers in immunology
Published: May 29, 2018
Showing 1-8 of 8

Last Updated: 09/26/2026